Asthma management with breath-triggered inhalers: innovation through design.
Asthma
Breath-triggered-inhalers
Control
Inhalers
Innovation
K-haler
Journal
Asthma research and practice
ISSN: 2054-7064
Titre abrégé: Asthma Res Pract
Pays: England
ID NLM: 101670236
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
05
2020
accepted:
25
05
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
11
6
2020
Statut:
epublish
Résumé
Asthma affects the lives of hundred million people around the World. Despite notable progresses in disease management, asthma control remains largely insufficient worldwide, influencing patients' wellbeing and quality of life. Poor patient handling of inhaling devices has been identified as a major persistent problem that significantly reduces inhaled drugs' efficacy and is associated with poor adherence to treatment, impairing clinical results such as asthma control and increasing disease-related costs. We herein review key research and development (R&D) innovation in inhaler devices, highlighting major real-world critical errors in the handling and inhalation technique with current devices and considering potential solutions. Furthermore, we discuss current evidence regarding breath-triggered inhalers (BTI). The two most common significant problems with inhalers are coordinating actuation and inhalation with pressurized metered-dose inhalers (pMDIs), and the need to inhale forcibly with a dry powder inhaler. BTI R&D plans were designed to overcome these problems. Its newest device k-haler® has several other important features, generating a less forceful aerosol plume than previous pMDIs, with efficient drug delivery and lung deposition, even in patients with low inspiratory flow. The local and systemic bioavailability of fluticasone propionate and formoterol (FP/FORM) administered via k-haler® has been shown to be therapeutically equivalent when administered via the previous FP/FORM pMDI. This device requires very few steps and has been considered easy to use (even at first attempt) and preferred by the patients in a randomized crossover study. In our country, FP/FORM k-haler is available without additional costs compared to FP/FORM pMDI. All devices continue to require education and regular checking of the correct inhalation technique. BTI R&D can bring advantage over current available inhalers, avoiding the two most common identified critical errors in inhalation technique. K-haler® BTI is currently available, without an increased cost, and approved for adolescents and adults with asthma in whom treatment with inhaled combined therapy with long-acting beta
Sections du résumé
BACKGROUND
BACKGROUND
Asthma affects the lives of hundred million people around the World. Despite notable progresses in disease management, asthma control remains largely insufficient worldwide, influencing patients' wellbeing and quality of life. Poor patient handling of inhaling devices has been identified as a major persistent problem that significantly reduces inhaled drugs' efficacy and is associated with poor adherence to treatment, impairing clinical results such as asthma control and increasing disease-related costs. We herein review key research and development (R&D) innovation in inhaler devices, highlighting major real-world critical errors in the handling and inhalation technique with current devices and considering potential solutions. Furthermore, we discuss current evidence regarding breath-triggered inhalers (BTI).
MAIN BODY
METHODS
The two most common significant problems with inhalers are coordinating actuation and inhalation with pressurized metered-dose inhalers (pMDIs), and the need to inhale forcibly with a dry powder inhaler. BTI R&D plans were designed to overcome these problems. Its newest device k-haler® has several other important features, generating a less forceful aerosol plume than previous pMDIs, with efficient drug delivery and lung deposition, even in patients with low inspiratory flow. The local and systemic bioavailability of fluticasone propionate and formoterol (FP/FORM) administered via k-haler® has been shown to be therapeutically equivalent when administered via the previous FP/FORM pMDI. This device requires very few steps and has been considered easy to use (even at first attempt) and preferred by the patients in a randomized crossover study. In our country, FP/FORM k-haler is available without additional costs compared to FP/FORM pMDI. All devices continue to require education and regular checking of the correct inhalation technique.
CONCLUSION
CONCLUSIONS
BTI R&D can bring advantage over current available inhalers, avoiding the two most common identified critical errors in inhalation technique. K-haler® BTI is currently available, without an increased cost, and approved for adolescents and adults with asthma in whom treatment with inhaled combined therapy with long-acting beta
Identifiants
pubmed: 32518663
doi: 10.1186/s40733-020-00057-7
pii: 57
pmc: PMC7275490
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
4Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsAn educational grant from Mundipharma Pharmaceuticals LTd’s is acknowledged.
Références
Prim Care Respir J. 2013 Dec;22(4):406-11
pubmed: 24042172
J Aerosol Med. 2003 Fall;16(3):249-54
pubmed: 14572322
Eur J Health Econ. 2018 Dec;19(9):1303-1318
pubmed: 29754324
J Aerosol Med Pulm Drug Deliv. 2010 Oct;23(5):323-8
pubmed: 20804428
Expert Rev Respir Med. 2014 Feb;8(1):89-99
pubmed: 24325614
Respir Med. 2006 Sep;100(9):1479-94
pubmed: 16495040
Eur Rev Med Pharmacol Sci. 2001 Jan-Feb;5(1):7-16
pubmed: 11860222
J Aerosol Med Pulm Drug Deliv. 2015 Apr;28(2):88-99
pubmed: 25004168
Prim Care Respir J. 2006 Dec;15(6):326-31
pubmed: 17092772
J Asthma Allergy. 2011;4:37-47
pubmed: 21698214
Int J Clin Pract. 1999 Jan-Feb;53(1):31-6
pubmed: 10344063
Health Technol Assess. 2001;5(26):1-149
pubmed: 11701099
Breathe (Sheff). 2018 Sep;14(3):216-224
pubmed: 30186519
Respir Med. 2018 May;138:107-114
pubmed: 29724381
J Asthma. 2016;53(3):321-9
pubmed: 26810934
Eur Rev Med Pharmacol Sci. 2009 Sep-Oct;13(5):323-30
pubmed: 19961037
Eur J Respir Dis. 1987 Feb;70(2):93-8
pubmed: 3817076
Respir Med. 2011 Dec;105(12):1815-22
pubmed: 21802271
World Allergy Organ J. 2015 Sep 10;8(1):26
pubmed: 26417397
Respir Care. 2005 Sep;50(9):1139-50
pubmed: 16122398
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1071-1081.e9
pubmed: 28286157
J Asthma. 2008 Mar;45(2):109-13
pubmed: 18350401
Br J Clin Pharmacol. 2005 Dec;60(6):605-10
pubmed: 16305584
Prim Care Respir J. 2007 Apr;16(2):71-81
pubmed: 17356785
Eur J Respir Dis. 1986 May;68(5):332-5
pubmed: 3732427
Age Ageing. 1991 Sep;20(5):379-82
pubmed: 1755396
J Aerosol Med Pulm Drug Deliv. 2016 Aug;29(4):311-27
pubmed: 26824873
Respir Med. 2011 Jun;105(6):930-8
pubmed: 21367593
Int J Chron Obstruct Pulmon Dis. 2016 Mar 21;11:597-602
pubmed: 27051283
Expert Opin Drug Deliv. 2019 Dec;16(12):1367-1380
pubmed: 31752560
Respir Med. 2013 Jan;107(1):37-46
pubmed: 23098685
J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):823-32
pubmed: 27587316
Respir Med. 2000 May;94(5):496-500
pubmed: 10868714
Respir Res. 2018 Jan 16;19(1):10
pubmed: 29338792
J Aerosol Med Pulm Drug Deliv. 2017 Dec;30(6):425-434
pubmed: 28683212
Chest. 2016 Aug;150(2):394-406
pubmed: 27060726
Asthma Res Pract. 2017 Jan 6;3:1
pubmed: 28078100
Eur Respir J. 2002 Feb;19(2):246-51
pubmed: 11866004
Allergy Asthma Clin Immunol. 2013 Mar 06;9(1):8
pubmed: 23510684
Rev Port Pneumol (2006). 2017 Nov - Dec;23(6):323-330
pubmed: 28807558
Respir Med. 2010 Sep;104(9):1237-45
pubmed: 20472415
Respir Med. 2008 Apr;102(4):593-604
pubmed: 18083019
Chest. 1993 Nov;104(5):1332-7
pubmed: 8222783
Expert Rev Respir Med. 2016 Aug;10(8):927-33
pubmed: 27227384
Eur Rev Med Pharmacol Sci. 2011 May;15(5):563-70
pubmed: 21744753
Thorax. 1991 Oct;46(10):712-6
pubmed: 1750017
Allergy Asthma Proc. 2018 Mar 9;39(2):117-126
pubmed: 29317015